Company Filing History:
Years Active: 2022
Title: Juergen Frevert: Innovator in Clostridial Neurotoxins
Introduction
Juergen Frevert is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant clostridial neurotoxins. His work has implications for various medical applications, showcasing the potential of innovative biopharmaceuticals.
Latest Patents
Juergen Frevert holds 1 patent for his invention titled "Recombinant clostridial neurotoxins with increased duration of effect." This invention relates to novel recombinant clostridial neurotoxins that exhibit an increased duration of effect. The methods for manufacturing these neurotoxins involve inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin. The expression of the recombinant nucleic acid sequence occurs in a host cell, leading to the production of these innovative neurotoxins. The invention also includes novel recombinant single-chain precursor clostridial neurotoxins and pharmaceutical compositions that utilize these advancements.
Career Highlights
Juergen Frevert is associated with Merz Pharma GmbH & Co. KGaA, where he continues to advance his research and development efforts. His work at Merz Pharma emphasizes the importance of innovation in the pharmaceutical industry, particularly in the realm of neurotoxin applications.
Collaborations
Throughout his career, Juergen has collaborated with esteemed colleagues such as Fred Hofmann and Michael Schmidt. These collaborations have fostered a productive environment for innovation and have contributed to the success of his research endeavors.
Conclusion
Juergen Frevert's contributions to the field of biotechnology, particularly through his patented work on recombinant clostridial neurotoxins, highlight the importance of innovation in medical science. His ongoing efforts at Merz Pharma and collaborations with fellow researchers continue to pave the way for advancements in therapeutic applications.